AI Article Synopsis
- Phaeochromocytomas and paragangliomas, though originating from the same chromaffin cells, exhibit distinct clinical characteristics and outcomes, indicating they should be viewed as separate entities.
- A study reviewed 106 patients treated between 1983 and 2012, revealing that symptoms and presentations varied, with paragangliomas showing a higher incidence of pain and malignancy compared to phaeochromocytomas.
- Malignant paragangliomas had lower MIBG uptake and poorer stabilization rates compared to malignant phaeochromocytomas, highlighting the need for different treatment approaches for each condition.
Article Abstract
Background: Phaeochromocytomas and paragangliomas arise from the same chromaffin cell, but evidence suggests they do not represent a single clinical entity. The aim of this study was to compare clinical presentations, outcomes of surgical and oncological treatments and survival in patients with phaeochromocytomas and paragangliomas.
Methods: A retrospective review was undertaken of all patients treated for these conditions at our centre between 1983 and 2012.
Results: One hundred and six patients (88 adults, 18 children) with phaeochromocytoma (n = 83) or paraganglioma (n = 23) were studied. Catecholamine symptoms and incidentalomas were the main presentations in phaeochromocytoma patients (67% and 17%) respectively, but in those with paragangliomas pain (39%) was more common (P < 0.001). More paragangliomas were malignant (14/23 vs 9/83, P < 0.0001), larger (9.17 ± 4.95 cm vs. 5.8 ± 3.44 cm, P = 0.001) and had a higher rate of conversion to open surgery (P = <0.01), more R2 resections, more postoperative complications and a longer hospital stay (P = 0.014). MIBG uptake in malignant paragangliomas was lower than in malignant phaeochromocytomas (36% vs. 100%, P = 0.002) and disease stabilisation was achieved in 29% and 86% of patients respectively. (90) Y-DOTA-octreotate had a 78% response rate in malignant paragangliomas.
Conclusion: The clinical differences between paragangliomas and phaeochromocytomas support the view that they should be considered as separate clinical entities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.24030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Pharmaceutical Composition of Rocuronium Bromide May Promote Catecholamine Release From PC-12 Cells.
Cureus
December 2024
Anesthesiology, Nihon University School of Medicine, Tokyo, JPN.
Background: Several cases of pheochromocytoma presenting with hypertensive crises after anesthesia induction, possibly caused by rocuronium injection, have been reported. Rocuronium has two compositions: rocuronium bromide (RB) in sodium acetate hydrate/acetic acid buffer solution (acetic acid vehicle) and RB in glycine/hydrochloric acid buffer solution (hydrochloric acid vehicle). This study assessed the effect of rocuronium composition on the release of catecholamine from PC-12 rat adrenal pheochromocytoma cells.
View Article and Find Full Text PDFPheochromocytoma (PHEO) currently is considered to be malignant due to metastatic potential. One of the most common familial forms of PHEO is multiple endocrine neoplasia syndrome (MEN) type 2. The penetrance of PHEO in MEN2 syndrome is up to 50% of cases.
View Article and Find Full Text PDFA Rare Case Report of Extra-adrenal Pheochromocytoma Masquerading as a Pancreatic Head Malignancy.
Cureus
December 2024
Internal Medicine, University of Florida College of Medicine, Pensacola, USA.
Extra-adrenal pheochromocytomas are rare neuroendocrine tumors originating outside the adrenal glands and can pose significant diagnostic challenges due to their variable presentations. This report highlights a case of an extra-adrenal pheochromocytoma masquerading as a pancreatic head malignancy. We underscore the importance of considering extra-adrenal pheochromocytoma in the differential diagnosis of pancreatic masses, particularly when biochemical or clinical features suggest catecholamine excess.
View Article and Find Full Text PDFMultiplexed Dilute-and-Shoot Liquid Chromatography-Multiple-Reaction Monitoring Mass Spectrometry Clinical Assay for Metanephrines and Catecholamines in Human Urine.
Metabolites
January 2025
Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Quantifying urinary catecholamines and metanephrines is essential for the clinical screening and diagnosis of neuroendocrine tumours. HPLC with electrochemical detection (HPLC-ECD) is commonly used for this type of analysis but requires extensive sample cleanup. Simple and rapid dilute-and-shoot LC-multiple-reaction monitoring (MRM)-MS assays have been developed for quantitating these analytes in urine but have not yet been validated according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
View Article and Find Full Text PDFResponse to the letter "OSIN-24-D-01312, letter to the editor commenting on 'evaluation of bone mineral density (BMD) and trabecular bone score (TBS) in pheochromocytoma and paraganglioma; a multi-centric case-control study from India'".
Osteoporos Int
January 2025
Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Nagpur, Room No 443, OPD Block, 4th Floor, Plot-2, Sector-20, Mihan, Nagpur, 441108, Maharashtra, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!